AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03997890 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery with binocular implantation of either Symfony (ZXR00) or Symfony toric (ZXT) IOLs
Description: After creating an initial side port incision with a 15-degree blade, 3-step clear corneal incisions were made using a 2.5 mm disposable metal blade. Sodium hyaluronate 1.0% (Healon; Abbott Medical Optics) was then injected into the anterior chamber. A continuous curvilinear capsulorrhexis, measuring 5.5 mm in diameter, was generated using a 26 gauge bent needle. After hydrodissection, phacoemulsification was done to remove nuclear fragments and aspiration of residual cortex. In all eyes, a Symfony or Symfony toric IOL was implanted in the capsular bag using a disposable implantation system. Irrigation and aspiration were performed to minimize ophthalmic viscoelastic surgical device retention at the end of surgery. The main incision and side port were sealed with stromal hydration using a balanced salt solution.
Study NCT04173611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL
Description: Injection into the Intrathecal space.
Study NCT03095599 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVACFLU-S
Description: IVACFLU-S is seasonal inactivated, split virion, trivalent influenza vaccine (A/H3N2, A/H1N1, and B), produced in GCP facility by IVAC uses embryonated chicken eggs. This vaccine is purified by sucrose gradient ultracentrifugation (Alfa Wassermann, West Caldwell, NJ), and inactivated with formaldehyde. Each 0.5 mL dose of vaccine contains~* NYMC X-179A (A/California/7/2009) (H1N1) - 15μg hemagglutinin (HA)~* NYMC X-263B (A/HongKong/4801/2014) (H3N2) - 15μg HA~* NYMC BX-35 (B/Brisbane/60/2008) (B) - 15μg HA
Study NCT04173611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Injection into the Intrathecal space.
Study NCT04173611 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Injection into the Intrathecal space.
Study NCT00156182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 10mg Tablet, oral Daily for 6 months
Study NCT04272437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concentrated herbal extract granules TRA
Description: Concentrated herbal extract granules Subjects in the TRA group orally ingested one package of granules (5 g/package) two times daily with warm water after lunch and dinner for 6 consecutive weeks.
Study NCT04272437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in the placebo group orally ingested one package of granules (5 g/package) two times daily with warm water after lunch and dinner for 6 consecutive weeks.
Study NCT03544242 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: A saline infusion will be administered during the pre-isolation and post-isolation phases.
Study NCT03544242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Isolation Infusion
Description: A nitrite infusion will be administered during the pre-isolation phase and a saline infusion will be administered during the post-isolation phase.
Study NCT04227522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: A starting dose of 600 mg Rucaparib is taken twice daily orally by the patients as maintenance after previous maintenance therapy (Bevacizumab) for a period of 12 to 15 months.
Study NCT04227522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo is taken daily orally by the patients as maintenance after previous maintenance therapy (Bevacizumab) for a period of 12 to 15 months.
Study NCT03544242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Isolation Infusion
Description: A saline infusion will be administered during the pre-isolation phase and a nitrite infusion will be administered during the reperfusion phase.
Study NCT00064324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perifosine
Description: Given orally
Study NCT00064324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03095599 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline with pH 7.2; 0.5 ml/per dose
Study NCT04689022 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mississippi Scale for Combat-Related PTSD (M-PTSD)
Description: The treatment outcome rate was assessed by the Mississippi Scale for Combat-Related PTSD (M-PTSD). A positive outcome rate is represented with the patient post-discharge positive coping, which corresponds to 94-58 points, observed in 39 patients (17.9%). A treatment failure is regarded as the absent PTSD treatment effect after discharge, which corresponds to 148-113 points, observed in 5 patients (2.3%) and psychic disorders, which correspond to 112-95 points, observed in 174 patients (79,8%).
Study NCT00064324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00690027 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Emergency portacaval shunt
Study NCT00690027 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Emergency and long-term endoscopic sclerotherapy
Study NCT02045108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Retraining
Study NCT02045108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham TDCS
Study NCT02045108 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TDCS
Study NCT02045108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TDCS
Study NCT02045108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sham Retraining
Study NCT02045108 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Retraining
Study NCT00976443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BTA
Description: BTA 100 or 300 U, endoscopic ultrasound (EUS) guided injections into gastric antrum
Study NCT03148171 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WERK Supportive Contact
Description: Provide emotional support and practical support. Support friend/family by helping him to stay engaged in PrEP Care.
Study NCT03509753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Fiber
Description: See intervention description.
Study NCT00976443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline)
Description: Placebo (normal saline), gastric injections of normal saline
Study NCT00828321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg capsule
Description: 1 x 10 mg
Study NCT00828321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Altace® 10 mg capsule
Description: 1 x 10 mg
Study NCT03444883 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ilaprazole
Description: 10mgx2 tablet once daily for weeks
Study NCT03444883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ilaprazole
Description: 10mgx2 tablet once daily for weeks
Study NCT03368209 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WM3.4
Description: Investigational Medical Device collecting spectral raman data from tissue.
Study NCT00003223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenretinide
Description: 200 mg/day PO, days 1-25 q 28 days x 6 cycles.
Study NCT04488380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dental restoration
Description: Restoration of carious mandibular 2nd molar teeth either with high viscosity glass ionomer or nanohybrid composite resin
Study NCT00323258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: oral education & written tips for remembering medications
Description: Clinical pharmacist will review purpose of medications of interest (beta-blockers, statins, Angiotensin Converting Enzyme Inhibitor (ACEI)/Angiotensin Receptor Blocker (ARB), aspirin, and other anti-platelets) with the subject. A written list of tips for remembering medications will be provided and reviewed.
Study NCT00323258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pill box
Description: Subject is provided a pill box and briefly instructed on how to use the box.
Study NCT00323258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pocket medication card
Description: Subject is provided with a card that contains space for prescription and non-prescription medications. If desired the clinical pharmacist-investigator will complete the card for the subject.
Study NCT00323258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sharing information with community pharmacist
Description: A fax is sent to the designated community pharmacy at the time of the subject's discharge from the hospital. The fax contains the subject's medications of interest, barriers to medication adherence, and physicians' contact information.
Study NCT00323258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication use evaluations by community pharmacist
Description: The community pharmacist will assess use of medications of interest at time of first medication fill and by reviewing the subject's computerized medication profile at the pharmacy. Assessments occur at first visit to pharmacy, 6-weeks, 12-weeks, 18-weeks, and 24-weeks. If there are issues with any medications of interest the subject will be called. If needed, the subject's health care team will be notified.
Study NCT00323258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: informing physician if patient has stopped a medication
Description: The community pharmacist or clinical pharmacist-investigator will fax the subject's physician to notify that a medication has been stopped.
Study NCT00323258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine discharge counseling
Description: Both groups received routine discharge counseling performed by the patient-care nurse.
Study NCT00323258 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine discharge counseling
Description: Both groups received routine discharge counseling performed by the patient-care nurse.
Study NCT03568058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: personalized vaccine
Description: Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.
Study NCT03509753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low Fiber
Description: See intervention description.
Study NCT02828319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-213
Description: The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV on day 1, 8 and 15 (if needed)
Study NCT04408157 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management booklet (SWitCh: Stay well during COVID-19)
Description: The purpose of this booklet is to support adjustment to the current circumstances of the COVID-19 pandemic and facilitate the development and maintenance of healthy behaviours at home. The booklet covers a range of topics, including understanding bodily sensations and symptoms of COVID-19, managing the uncertainty surrounding COVID-19, physical activity, sedentary behaviour, sleep, social support and isolation, nutrition and alcohol consumption, sex and intimate relationships, and coping with children at home. The booklet will provide structured guidance on the various topics through the use of effective behaviour change techniques, in particular self-monitoring, goal setting, and problem solving and signposting to additional helpful resources, such as drinking or nutrition tracking apps.
Study NCT03667677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tandospirone + Amlodipine
Description: The first group will receive a 30 mg dose of tandospirone one day( a 10 mg dose of tandospirone each time and three times a day) and a 5 mg dose of amlodipine one day(a 5 mg dose of amlodipine and one time a day).
Study NCT03667677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tandospirone placebo + Amlodipine
Description: The second group will receive a 30 mg dose of tandospirone placebo one day( a 10 mg dose of tandospirone placebo each time and three times a day) and a 5 mg dose of amlodipine one day(a 5 mg dose of amlodipine and one time a day).
Study NCT03667677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tandospirone + Amlodipine placebo
Description: The third group will receive a 30 mg dose of tandospirone one day( a 10 mg dose of tandospirone and three times a day) and a 5 mg dose of amlodipine placebo one day(a 5 mg dose of amlodipine placebo and one time a day).
Study NCT03667677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tandospirone placebo + Amlodipine placebo
Description: The fourth group will receive a 30 mg dose of tandospirone placebo one day( a 10 mg dose of tandospirone placebo each time and three times a day) and a 5 mg dose of amlodipine placebo one day(a 5 mg dose of amlodipine placebo and one time a day).
Study NCT00778999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marvelon
Description: oral contraceptive 1 tablet daily for 14 to 21 days
Study NCT03587909 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification Cataract SUrgery
Description: Phacoemulsification in eyes with shallow anterior chamber (\<2.5mm depth)
Study NCT03587909 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femtosecond Cataract Surgery
Description: Femtosecond Cataract Surgery in eyes with shallow anterior chamber \< 2.5mm
Study NCT02857023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed RM
Description: Cogmed consists of 12 increasingly challenging exercises (completed over 25 sessions spanning 5-8 weeks) that target skills involving visuo-spatial and verbal working memory.
Study NCT02168946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vabomere
Description: Vabomere for IV injection, administered as a 2 g/2 g dose
Study NCT02168946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy
Description: Antibiotic(s) chosen by Investigator
Study NCT04374994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avanafil 50 MG
Description: Oral phosphodiesterase type 5 inhibitors
Study NCT04374994 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: lactose and maize starch, Egypt
Study NCT02199522 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: titration induction to propofol
Description: propofol intravenously by Fresenius pump at the speed of 1 mg•kg-1•min-1, and OAA/S scale of the patients was titrated to 1
Study NCT02235285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: primary breast augmentation
Description: With the patient under sedative anesthesia, wide preparation and draping by using povidone-iodine are performed with using talc-free gloves and povidone-iodine gauze nipple shields. Tumescent solution is infiltrated in the precise plane. Pockets are developed precisely with blunt dissection with fingers and instruments under both direct and indirect visions simultaneously, if needed, with using endoscopy, while careful hemostasis done. After dissection, two pockets are irrigated with 300ml of single antibiotic solution without active evacuation of the irrigation. When re-draping and re-preparation by using povidone-iodine are performed before implant insertion, a new pair of talc-free gloves is used and cleansed with the single antibiotic solution.
Study NCT04208373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64417184
Description: JNJ 64417184 tablets will be administered orally.
Study NCT04208373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole capsules will be administered orally
Study NCT04208373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine
Description: etravirine tables will be administered orally.
Study NCT04799782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: 15 mg dose before bed-time
Study NCT04799782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo pill before bed-time
Study NCT02457897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liothyronine
Description: Oral supplement given every 8 hours
Study NCT03445039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: traditional TSFE
Description: The TSFE procedure is performed by osteotomes (Straumann AG, Basel, Switzland) and mallet as the traditional ways.
Study NCT03445039 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone grafting materials
Description: The bone substitute is placed into the siuns under the membrane before the implant placement
Study NCT03445039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TSFE by DASK drills
Description: The TSFE procedure is performed by DASK(Dentium Advanced Surgical Kits) drills (Dentium, Korea), the residual cortical plate of the sinus floor is grinded by the drills.
Study NCT03445039 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: without bone grafting materials
Description: The bone substitute will not be placed into the sinus before the implant placement.
Study NCT00399802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZA
Description: Single ZA 4 mg IV infusion at the start of treatment
Study NCT00399802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: Once-daily odanacatib 5 mg tablet for 4 weeks
Study NCT00399802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Odanacatib matching placebo
Description: Once-daily odanacatib matching placebo for 4 weeks
Study NCT03568058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg pembrolizumab will be administered intravenous (IV) infusion every 3 weeks.
Study NCT00399802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZA matching placebo
Description: Single IV infusion of ZA matching placebo given at the start of treatment
Study NCT04689022 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: visual analogue scale (VAS)
Description: pain intensity
Study NCT04689022 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Douleur Neuropathique 4 questions (DN4)
Description: neuropathic pain component
Study NCT02959138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanraplenib.
Description: 20 mg (2 X 10 mg) tablets administered orally in a fasted state on Day 1
Study NCT02391038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0264
Description: MLN0264 IV.
Study NCT03401177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen 500 Mg
Description: Naproxen is used as a tool to dampen the inflammation thought to be present in early phase Tendinopathy
Study NCT03401177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo is used, to provide a control to the active group.
Study NCT03401177 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heavy resistance training
Description: Heavy slow resistance training - used in both groups subsequent to the initial week of NSAID or placebo treatment.
Study NCT03401177 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Heavy resistance training
Description: Heavy slow resistance training - used in both groups subsequent to the initial week of NSAID or placebo treatment.
Study NCT02366208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-Tα1
Description: 1.6 mg/ml, once a week, taken subcutaneously
Study NCT02366208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match PEG-Tα1
Description: 1ml, once a week, taken subcutaneously
Study NCT03134963 — intervention group
Intervention type: OTHER
Intervention: Transcranial doppler ultrasonography
Description: Measurement of cerebral blood flow whilst undertaking cognitive tasks with TCD monitoring.
Study NCT03134963 — intervention group
Intervention type: OTHER
Intervention: Blood pressure monitoring
Description: Continuous blood pressure recording
Study NCT02366208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir
Description: 10 mg, once daily, taken orally for 48 weeks
Study NCT02366208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adefovir
Description: 10 mg, once daily, taken orally for 48 weeks
Study NCT00680303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Lidcombe Program for early stuttering
Study NCT00680303 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The Lidcombe Program for early stuttering
Study NCT00632710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phototherapy
Description: The laser used was low-level Aluminum Gallium Arsenide (AlGaAs)diodo laser, at a wavelength of 785 nm (infrared), dose of 3 J/cm2, mean power of 70 mW, 3 sec. per point, laser beam of 0,06cm2, BIOSET brand - Indústria de Tecnologia Eletrônica Ltda -Rio Claro, Brazil.
Study NCT00632710 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: phototherapy placebo
Description: disconnected laser (same device - experimental group)
Study NCT01755689 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One dose administered intramuscularly (IM) in the deltoid of the right arm.